Brentuximab – Uses, Dosage, Side Effects, Interaction Brentuximab vedotin is a CD30-directed antibody-drug conjugate used to treat various types of lymphoma. Brentuximab vedotin, also known as Adcetris, is an antibody-drug conjugate that combines an anti-CD30 antibody with the drug monomethyl auristatin E (MMAE). It is an anti-neoplastic agent used in the treatment of Hodgkin’s lymphoma and systemic anaplastic large-cell lymphoma. Brentuximab vedotin was initially approved in 2011. In January 2012, the drug label was revised with a boxed warning of a condition known as progressive multifocal leukoencephalopathy and death due to opportunistic JC virus infection post-treatment [rx]. The U.S. Food and Drug Administration approved Adcetris in March 2018 to treat adult patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy [rx]. Adcetris has also been previously approved by the FDA to treat Hodgkin’s lymphoma after relapse, Hodgkin’s lymphoma after stem cell transplantation when a patient has a high risk of relapse or progression, systemic anaplastic large cell lymphoma (ALCL) after the failure of other treatment regimens, and primary cutaneous ALCL after the failure of other treatment regimens [rx]. Lymphoma is a malignancy that begins in the lymphatic system, which helps to combat infection and disease. Lymphoma may begin anywhere in the body and can spread to nearby lymph nodes. The two main types of lymphoma are Hodgkin lymphoma (also called Hodgkin disease) and non-Hodgkin lymphoma. Most individuals with Hodgkin’s lymphoma have the classical type. In this type of lymphoma, large, abnormal lymphocytes (a type of white blood cell) are found in the lymph nodes called Reed-Sternberg cells. With early diagnosis and intervention, patients with Hodgkin lymphoma normally experience long-term remission [rx]. The ECHELON-1 study results demonstrated the superior efficacy of the drug combined with a chemotherapy regimen when it is compared to the previous standard of care. Importantly, removing the drug bleomycin, a highly toxic agent, was completely removed from the regimen. This demonstrates meaningful progress in treatment for patients affected by this disease [rx]. Mechanism of action Brentuximab vedotin is composed of 3 parts: a chimeric human-murine IgG1 that selectively targets CD30, monomethyl auristatin E (MMAE), which is a microtubule-disrupting agent, and a protease-susceptible linker that links the antibody and MMAE. The IgG1 antibody enables Brentuximab vedotin to target tumor cells expressing CD30 on their surface. Following this Brentuximab vedotin enters the cell. Once inside, the linker is cleaved releasing MMAE which binds and disrupts the microtubule network.[rx] The antibody component of this drug is a chimeric IgG1 directed against CD30. The small molecule, MMAE, is a microtubule-disrupting particle. MMAE is covalently attached to the antibody by a linker. Data suggest that the anticancer activity of Adcertris is due to the binding of the ADC to CD30-expressing cells, followed by internalization of the ADC-CD30 complex, and the subsequent release of MMAE by proteolytic cleavage. The binding of MMAE to tubulin disrupts the microtubule network within the cell, inducing cell cycle arrest and apoptosis of the malignant cells Indications Brentuximab vedotin is indicated in adult patients for the treatment of previously untreated stage III or IV classical Hodgkin’s lymphoma (cHL) in combination with doxorubicin, vinblastine, and dacarbazine. It is also indicated for the treatment of cHL post-autologous hematopoietic stem cell transplantation (auto-HSCT) in patients at high risk of relapse or progression. Finally, it may be used in the treatment of adult patients with cHL who have previously failed either auto-HSCT or at least two prior multi-agent chemotherapy regimens if they are not candidates for auto-HSCT.[rx] Brentuximab vedotin is additionally indicated in the treatment of previously untreated systemic anaplastic large cell lymphoma (sALCL), or other CD30-expressing peripheral T-cell lymphomas (PTCL), in combination with cyclophosphamide, doxorubicin, and prednisone. It may also be used as monotherapy in sALCL after the therapeutic failure of a least one prior multi-agent chemotherapy regimen.[rx] Brentuximab vedotin is also indicated in the treatment of primary cutaneous large anaplastic large cell lymphoma, or CD30-expressing mycosis fungoides, who have received prior systemic therapy.[rx] CD30-expressing Mycosis Fungoides (MF) Classical Hodgkin’s Lymphoma Peripheral T Cell Lymphoma (PTCL) Primary Cutaneous Anaplastic Large Cell Lymphoma Systemic Anaplastic Large Cell Lymphoma Stage 3 Classical Hodgkin’s Lymphoma Brentuximab vedotin is an anti-neoplastic agent used in the treatment of Hodgkin’s lymphoma [PMID:25796459] and systemic anaplastic large-cell lymphoma. Several clinical trials are evaluating the combination of brentuximab vedotin with immune checkpoint inhibitors, to assess any synergistic effects as a result of dual targeting. Checkpoint inhibitors being investigated in this way include nivolumab and pembrolizumab (both anti-PD-1), and ipilimumab (anti-CTLA4). Brentuximab vedotin + pembrolizumab (NCT02684292) and brentuximab vedotin + nivolumab (NCT03138499) are both Phase 3 studies in patients with relapsed/refractory classical Hodgkin’s lymphoma. Expanded approvals:In November 2017, the FDA approved brentuximab vedotin for the treatment of adult patients with primary cutaneous anaplastic large cell lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy, following review of results from the Phase 3 ALCANZA trial (NCT01578499) . In March 2018, the FDA approved the use of brentuximab vedotin for the treatment of patients with previously untreated stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy. This expansion was based on results from the ECHELON-1 clinical trial (NCT01712490). November 2018 saw further expansion of approval for the use of brentuximab vedotin plus chemotherapy for adult patients who are newly diagnosed with CD30-expressing peripheral T-cell lymphomas. Use in Cancer Brentuximab vedotin is approved for use in adults to treat: Anaplastic large cell lymphoma. Brentuximab vedotin is used in: Patients whose cancer is systemic (affects the whole body) and has not gotten better after treatment with combination chemotherapy. Patients whose cancer has not been treated. is given with cyclophosphamide, doxorubicin hydrochloride, and prednisone. Cutaneous anaplastic large cell lymphoma is primary. Brentuximab vedotin is used in patients who have received other systemic therapy. Hodgkin lymphoma. Brentuximab vedotin is used: After an autologous stem cell transplant (ASCT) patients who have a high risk that cancer will recur (come back) or get worse. In patients whose cancer has not gotten better after an ASCT. Brentuximab vedotin is also used in patients whose cancer has not gotten better after at least two treatments with combination chemotherapy and who cannot receive an ASCT. With chemotherapy in patients with stage III or stage IV Hodgkin lymphoma whose cancer has not been treated. Mycosis fungoides (a type of cutaneous T-cell lymphoma). Brentuximab vedotin is used in patients whose cancer has the CD30 protein and who have received other systemic therapy. Peripheral T-cell lymphoma that has the CD30 protein. Brentuximab vedotin is given with cyclophosphamide, doxorubicin hydrochloride, and prednisone. Brentuximab vedotin is also being studied in the treatment of other conditions and types of cancer. Contraindications a bad infection anemia decreased blood platelets low levels of a type of white blood cell called neutrophils a painful condition that affects the nerves in the legs and arms called peripheral neuropathy a type of inflammation of the lung called interstitial pneumonitis pregnancy a patient who is producing milk and breastfeeding a rupture in the wall of the stomach or intestine progressive multifocal leukoencephalopathy, a type of brain infection chronic kidney disease stage 4 (severe) chronic kidney disease stage 5 (failure) kidney disease with likely reduction in kidney function Child-Pugh class B liver impairment Child-Pugh class C liver impairment Dosage Strengths: 50 mg Hodgkin’s Disease Previously Untreated State III or IV Classical Hodgkin Lymphoma: 1.2 mg/kg (maximum 120 mg) IV over 30 minutes in combination with chemotherapy; administer every 2 weeks until a maximum of 12 doses, disease progression, or unacceptable toxicity Classical Hodgkin Lymphoma Consolidation: 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; initiate therapy within 4 to 6 weeks post-auto-HSCT or upon recovery from auto-HSCT; administer every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity Relapsed Classical Hodgkin Lymphoma: 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; administer every 3 weeks until disease progression or unacceptable toxicity Relapsed Primary Cutaneous Anaplastic Large Cell Lymphoma or DC30-Expressing Mycosis Fungoides (MF): 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; administer every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity Relapsed Systemic Anaplastic Large Cell Lymphoma: 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; administer every 3 weeks until disease progression or unacceptable toxicity The dose for patients weighing more than 100 kg should be calculated based on a weight of 100 kg. In patients with previously untreated Stage III or IV cHL who are treated with this drug plus doxorubicin/ vinblastine/dacarbazine (AVD), administer G-CSF beginning with Cycle 1. For previously untreated Stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy For adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation For adults with cHL after the failure of auto-HSCT or after failure of at least 2 prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates For adults with systemic anaplastic large cell lymphoma (sALCL) after the failure of at least one prior multi-agent chemotherapy regimen For adults with pcALCL or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy Mycosis Fungoides Previously Untreated Stage III or IV Classical Hodgkin Lymphoma: 1.2 mg/kg (maximum 120 mg) IV over 30 minutes in combination with chemotherapy; administer every 2 weeks until a maximum of 12 doses, disease progression, or unacceptable toxicity Classical Hodgkin Lymphoma Consolidation: 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; initiate therapy within 4 to 6 weeks post-auto-HSCT or upon recovery from auto-HSCT; administer every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity Relapsed Classical Hodgkin Lymphoma: 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; administer every 3 weeks until disease progression or unacceptable toxicity Relapsed Primary Cutaneous Anaplastic Large Cell Lymphoma or DC30-Expressing Mycosis Fungoides (MF): 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; administer every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity Relapsed Systemic Anaplastic Large Cell Lymphoma: 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; administer every 3 weeks until disease progression or unacceptable toxicity The dose for patients weighing more than 100 kg should be calculated based on a weight of 100 kg. In patients with previously untreated Stage III or IV cHL who are treated with this drug plus doxorubicin/ vinblastine/dacarbazine (AVD), administer G-CSF beginning with Cycle 1. For previously untreated Stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy For adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation For adults with cHL after the failure of auto-HSCT or after failure of at least 2 prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates For adults with systemic anaplastic large cell lymphoma (sALCL) after the failure of at least one prior multi-agent chemotherapy regimen For adults with pcALCL or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy Lymphoma Previously Untreated Stage III or IV Classical Hodgkin Lymphoma: 1.2 mg/kg (maximum 120 mg) IV over 30 minutes in combination with chemotherapy; administer every 2 weeks until a maximum of 12 doses, disease progression, or unacceptable toxicity Classical Hodgkin Lymphoma Consolidation: 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; initiate therapy within 4 to 6 weeks post-auto-HSCT or upon recovery from auto-HSCT; administer every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity Relapsed Classical Hodgkin Lymphoma: 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; administer every 3 weeks until disease progression or unacceptable toxicity Relapsed Primary Cutaneous Anaplastic Large Cell Lymphoma or DC30-Expressing Mycosis Fungoides (MF): 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; administer every 3 weeks until a maximum of 16 cycles, disease progression, or unacceptable toxicity Relapsed Systemic Anaplastic Large Cell Lymphoma: 1.8 mg/kg (maximum 180 mg) IV over 30 minutes; administer every 3 weeks until disease progression or unacceptable toxicity The dose for patients weighing more than 100 kg should be calculated based on a weight of 100 kg. In patients with previously untreated Stage III or IV cHL who are treated with this drug plus doxorubicin/ vinblastine/dacarbazine (AVD), administer G-CSF beginning with Cycle 1. For previously untreated Stage III or IV classical Hodgkin lymphoma (cHL) in combination with chemotherapy For adult patients with cHL at high risk of relapse or progression as post-autologous hematopoietic stem cell transplantation (auto-HSCT) consolidation For adults with cHL after the failure of auto-HSCT or after failure of at least 2 prior multi-agent chemotherapy regimens in patients who are not auto-HSCT candidates For adults with systemic anaplastic large cell lymphoma (sALCL) after the failure of at least one prior multi-agent chemotherapy regimen For adults with pcALCL or CD30-expressing mycosis fungoides (MF) who have received prior systemic therapy Liver Dose Adjustments Mild hepatic impairment (Child-Pugh A) If the recommended dose is 1.2 mg/kg (maximum 120 mg) IV over 30 minutes every 2 weeks, reduce the dose to 0.9 mg/kg (maximum 90 mg) IV over 30 minutes every 2 weeks; the dose for patients weighing greater than 100 kg should be calculated based on a weight of 100 kg If the recommended dose is 1.8 mg/kg (maximum 180 mg) IV over 30 minutes every 3 weeks, reduce the dose to 1.2 mg/kg (maximum 120 mg) IV over 30 minutes every 3 weeks; the dose for patients weighing greater than 100 kg should be calculated based on a weight of 100 kg Moderate (Child-Pugh B) to severe (Child-Pugh C) hepatic impairment: Not recommended. Dose Adjustments Peripheral Neuropathy/Neutropenia: GRADE 3 OR 4: If the recommended dose is 1.2 mg/kg (maximum 120 mg) IV over 30 minutes every 2 weeks, administer G-CSF prophylaxis for subsequent cycles for patients not receiving primary G-CSF prophylaxis. If the recommended dose is 1.8 mg/kg (maximum 180 mg) IV over 30 minutes every 3 weeks, hold dosing until improvement to baseline or Grade 2 or lower and consider G-CSF prophylaxis for subsequent cycles; for recurrent Grade 4 despite G-CSF prophylaxis consider discontinuing therapy or reduce the dose to 1.2 mg/kg up to a maximum of 120 mg every 3 weeks. Side Effects The Most Common constipation mouth sores decreased appetite weight loss tiredness dizziness weakness difficulty falling asleep or staying asleep anxiety dry skin hair loss night sweats joint, bone, muscle, back, arm, or leg pain muscle spasms More Common unusual bleeding or bruising numbness, burning, or tingling in the hands, arms, feet, or legs muscle weakness peeling or blistering skin hives rash itching nausea vomiting diarrhea cough or shortness of breath decreased urination swelling of the hands, feet, ankles, or lower legs difficult, painful, or frequent urination fever, chills, cough, or other signs of infection ongoing pain that begins in the stomach area but may spread to the back pale skin yellowing of the skin or eyes pain or discomfort in the right upper stomach area dark urine clay-colored bowel movements stomach pain unusual bleeding or bruising black and tarry stools red blood in stools Rare numbness, weakness, burning pain, tingly feeling, or loss of feeling in your arms or legs; sudden chest pain or discomfort, wheezing, dry cough, feeling short of breath; pain or burning when you urinate; high blood sugar–increased thirst, increased urination, dry mouth, fruity breath odor; ketoacidosis (too much acid in the blood)- nausea, vomiting, stomach pain, confusion, unusual drowsiness, or trouble breathing; or low blood cell counts–fever, chills, tiredness, mouth sores, skin sores, easy bruising, unusual bleeding, pale skin, cold hands and feet, feeling light-headed or short of breath; signs of tumor cell breakdown–confusion, weakness, muscle cramps, nausea, vomiting, fast or slow heart rate, decreased urination, tingling in your hands and feet or around your mouth; pancreatitis–severe pain in your upper stomach spreading to your back, nausea and vomiting; liver problems–loss of appetite, stomach pain (upper right side), tiredness, dark urine, jaundice (yellowing of the skin or eyes); or stomach problems–severe constipation, new or worsening stomach pain, bloody or tarry stools, coughing up blood or vomit that looks like coffee grounds. Interaction DRUG INTERACTION Abametapir The serum concentration of Brentuximab vedotin can be increased when it is combined with Abametapir. Abatacept The metabolism of Brentuximab vedotin can be increased when combined with Abatacept. Abciximab The risk or severity of adverse effects can be increased when Abciximab is combined with Brentuximab vedotin. Abemaciclib The metabolism of Abemaciclib can be decreased when combined with Brentuximab vedotin. Abrocitinib The serum concentration of Brentuximab vedotin can be increased when it is combined with Abrocitinib. Acalabrutinib The metabolism of Brentuximab vedotin can be decreased when combined with Acalabrutinib. Acenocoumarol The serum concentration of Acenocoumarol can be increased when it is combined with Brentuximab vedotin. Acetaminophen The metabolism of Brentuximab vedotin can be increased when combined with Acetaminophen. Acetazolamide The metabolism of Brentuximab vedotin can be decreased when combined with Acetazolamide. Adalimumab The metabolism of Brentuximab vedotin can be increased when combined with Adalimumab. Adenovirus The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Brentuximab vedotin. Aducanumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Aducanumab. Afatinib The serum concentration of Brentuximab vedotin can be increased when it is combined with Afatinib. Albendazole The metabolism of Brentuximab vedotin can be decreased when combined with Albendazole. Aldesleukin The metabolism of Brentuximab vedotin can be decreased when combined with Aldesleukin. Alectinib The metabolism of Alectinib can be decreased when combined with Brentuximab vedotin. Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Brentuximab vedotin. Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Brentuximab vedotin. Alfuzosin The metabolism of Alfuzosin can be decreased when combined with Brentuximab vedotin. Alirocumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Alirocumab. Allogeneic processed The therapeutic efficacy of Allogeneic processed thymus tissue can be decreased when used in combination with Brentuximab vedotin. Alpelisib The metabolism of Brentuximab vedotin can be increased when combined with Alpelisib. Alprazolam The metabolism of Alprazolam can be decreased when combined with Brentuximab vedotin. Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Brentuximab vedotin. Ambrisentan The serum concentration of Brentuximab vedotin can be increased when it is combined with Ambrisentan. Aminoglutethimide The metabolism of Brentuximab vedotin can be increased when combined with Aminoglutethimide. Aminophylline The metabolism of Aminophylline can be decreased when combined with Brentuximab vedotin. Amiodarone The serum concentration of Brentuximab vedotin can be increased when it is combined with Amiodarone. Amivantamab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Amivantamab. Amobarbital The metabolism of Brentuximab vedotin can be increased when combined with Amobarbital. Amprenavir The metabolism of Brentuximab vedotin can be decreased when combined with Amprenavir. Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Brentuximab vedotin. Anakinra The metabolism of Brentuximab vedotin can be increased when combined with Anakinra. Anifrolumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Anifrolumab. Ansuvimab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ansuvimab. Anthrax immune The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Brentuximab vedotin. Anthrax vaccine The risk or severity of infection can be increased when Anthrax vaccine is combined with Brentuximab vedotin. Antilymphocyte The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Antilymphocyte immunoglobulin (horse). Antithymocyte The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Brentuximab vedotin. Apalutamide The serum concentration of Brentuximab vedotin can be decreased when it is combined with Apalutamide. Apixaban The serum concentration of Brentuximab vedotin can be increased when it is combined with Apixaban. Apremilast The metabolism of Brentuximab vedotin can be increased when combined with Apremilast. Aprepitant The metabolism of Brentuximab vedotin can be decreased when combined with Aprepitant. Aripiprazole The metabolism of Aripiprazole can be decreased when combined with Brentuximab vedotin. Aripiprazole lauroxil The metabolism of Aripiprazole lauroxil can be decreased when combined with Brentuximab vedotin. Armodafinil The metabolism of Brentuximab vedotin can be increased when combined with Armodafinil. Arsenic trioxide The serum concentration of Brentuximab vedotin can be increased when it is combined with Arsenic trioxide. Articaine The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Articaine. Asciminib The serum concentration of Brentuximab vedotin can be increased when it is combined with Asciminib. Asfotase alfa The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Asfotase alfa. Astemizole The metabolism of Brentuximab vedotin can be decreased when combined with Astemizole. COVID-19 Vaccine The therapeutic efficacy of AstraZeneca COVID-19 Vaccine can be decreased when used in combination with Brentuximab vedotin. Asunaprevir The serum concentration of Brentuximab vedotin can be increased when it is combined with Asunaprevir. Atazanavir The metabolism of Brentuximab vedotin can be decreased when combined with Atazanavir. Atezolizumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Atezolizumab. Atoltivimab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Atoltivimab. Atorvastatin The metabolism of Atorvastatin can be decreased when combined with Brentuximab vedotin. Avacopan The metabolism of Brentuximab vedotin can be decreased when combined with Avacopan. Avanafil The serum concentration of Avanafil can be increased when it is combined with Brentuximab vedotin. Avatrombopag The serum concentration of Brentuximab vedotin can be increased when it is combined with Avatrombopag. Avelumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Avelumab. Axitinib The metabolism of Axitinib can be decreased when combined with Brentuximab vedotin. Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Brentuximab vedotin. Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Brentuximab vedotin. Azithromycin The metabolism of Brentuximab vedotin can be decreased when combined with Azithromycin. Bacillus The risk or severity of infection can be increased when Bacillus calmette-guerin substrain connaught live antigen is combined with Brentuximab vedotin. Bacillus The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Brentuximab vedotin. Bacillus The risk or severity of infection can be increased when Bacillus calmette-guerin substrain tice live antigen is combined with Brentuximab vedotin. Bamlanivimab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bamlanivimab. Baricitinib The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Baricitinib. Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Brentuximab vedotin. BCG vaccine The risk or severity of infection can be increased when BCG vaccine is combined with Brentuximab vedotin. Bebtelovimab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bebtelovimab. Beclomethasone The metabolism of Brentuximab vedotin can be increased when combined with Beclomethasone dipropionate. Belantamab mafodotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Belantamab mafodotin. Belatacept The risk or severity of adverse effects can be increased when Belatacept is combined with Brentuximab vedotin. Belimumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Belimumab. Belinostat The risk or severity of adverse effects can be increased when Belinostat is combined with Brentuximab vedotin. Belumosudil The serum concentration of Brentuximab vedotin can be increased when it is combined with Belumosudil. Belzutifan The serum concentration of Brentuximab vedotin can be decreased when it is combined with Belzutifan. Bendamustine The risk or severity of adverse effects can be increased when Bendamustine is combined with Brentuximab vedotin. Benralizumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Benralizumab. Benzocaine The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Benzocaine. Benzyl alcohol The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Benzyl alcohol. Berotralstat The serum concentration of Brentuximab vedotin can be increased when it is combined with Berotralstat. Besilesomab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Besilesomab. Betamethasone The metabolism of Brentuximab vedotin can be increased when combined with Betamethasone. Betamethasone phosphate The metabolism of Brentuximab vedotin can be increased when combined with Betamethasone phosphate. Betrixaban The serum concentration of Brentuximab vedotin can be increased when it is combined with Betrixaban. Bevacizumab The risk or severity of adverse effects can be increased when Bevacizumab is combined with Brentuximab vedotin. Bexarotene The metabolism of Brentuximab vedotin can be increased when combined with Bexarotene. Bezlotoxumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Bezlotoxumab. Bicalutamide The metabolism of Brentuximab vedotin can be decreased when combined with Bicalutamide. Bifonazole The metabolism of Brentuximab vedotin can be decreased when combined with Bifonazole. Bimekizumab The metabolism of Brentuximab vedotin can be increased when combined with Bimekizumab. Bisoprolol The serum concentration of Brentuximab vedotin can be increased when it is combined with Bisoprolol. Bleomycin The risk or severity of pulmonary toxicity can be increased when Brentuximab vedotin is combined with Bleomycin. Blinatumomab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Blinatumomab. Boceprevir The metabolism of Brentuximab vedotin can be decreased when combined with Boceprevir. You Might Also Read What Is Prabotulinumtoxin A? Indications, Contraindications Bortezomib The metabolism of Bortezomib can be decreased when combined with Brentuximab vedotin. Bosentan The metabolism of Brentuximab vedotin can be increased when combined with Bosentan. Bosutinib The metabolism of Brentuximab vedotin can be decreased when combined with Bosutinib. Brigatinib The metabolism of Brigatinib can be decreased when combined with Brentuximab vedotin. Brodalumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Brodalumab. Brolucizumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Brolucizumab. Budesonide The metabolism of Brentuximab vedotin can be increased when combined with Budesonide. Bupivacaine The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Bupivacaine. Buprenorphine The metabolism of Brentuximab vedotin can be decreased when combined with Buprenorphine. Burosumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Burosumab. Busulfan The metabolism of Busulfan can be decreased when combined with Brentuximab vedotin. Butacaine The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Butacaine. Butalbital The metabolism of Brentuximab vedotin can be increased when combined with Butalbital. Butamben The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Butamben. Cabazitaxel The metabolism of Cabazitaxel can be decreased when combined with Brentuximab vedotin. Cabergoline The metabolism of Cabergoline can be decreased when combined with Brentuximab vedotin. Calcitriol The metabolism of Brentuximab vedotin can be increased when combined with Calcitriol. Canagliflozin The serum concentration of Brentuximab vedotin can be increased when it is combined with Canagliflozin. Canakinumab The metabolism of Brentuximab vedotin can be increased when combined with Canakinumab. Candicidin The metabolism of Brentuximab vedotin can be decreased when combined with Candicidin. Cannabidiol The metabolism of Brentuximab vedotin can be decreased when combined with Cannabidiol. Capecitabine The risk or severity of adverse effects can be increased when Capecitabine is combined with Brentuximab vedotin. Caplacizumab The risk or severity of adverse effects can be increased when Caplacizumab is combined with Brentuximab vedotin. Capmatinib The serum concentration of Brentuximab vedotin can be increased when it is combined with Capmatinib. Capromab pendetide The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Brentuximab vedotin. Capsaicin The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Capsaicin. Carbamazepine The metabolism of Brentuximab vedotin can be increased when combined with Carbamazepine. Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Brentuximab vedotin. Carfilzomib The serum concentration of Brentuximab vedotin can be increased when it is combined with Carfilzomib. Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Brentuximab vedotin. Carvedilol The serum concentration of Brentuximab vedotin can be increased when it is combined with Carvedilol. Casirivimab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Casirivimab. Catumaxomab The risk or severity of adverse effects can be increased when Catumaxomab is combined with Brentuximab vedotin. Cefradine The metabolism of Brentuximab vedotin can be increased when combined with Cefradine. Cemiplimab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Cemiplimab. Cenobamate The serum concentration of Brentuximab vedotin can be decreased when it is combined with Cenobamate. Cephalexin The metabolism of Brentuximab vedotin can be decreased when combined with Cephalexin. Ceritinib The metabolism of Brentuximab vedotin can be decreased when combined with Ceritinib. Cerivastatin The metabolism of Brentuximab vedotin can be increased when combined with Cerivastatin. Certolizumab pegol The metabolism of Brentuximab vedotin can be increased when combined with Certolizumab pegol. Cetuximab The risk or severity of adverse effects can be increased when Cetuximab is combined with Brentuximab vedotin. Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Brentuximab vedotin. Chloramphenicol The metabolism of Brentuximab vedotin can be decreased when combined with Chloramphenicol. Chloroprocaine The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Chloroprocaine. Chlorpromazine The metabolism of Brentuximab vedotin can be increased when combined with Chlorpromazine. Ciclesonide The risk or severity of adverse effects can be increased when Ciclesonide is combined with Brentuximab vedotin. Cilgavimab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Cilgavimab. Cilostazol The metabolism of Cilostazol can be decreased when combined with Brentuximab vedotin. Cimetidine The metabolism of Brentuximab vedotin can be decreased when combined with Cimetidine. Cinchocaine The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Cinchocaine. Ciprofloxacin The metabolism of Brentuximab vedotin can be decreased when combined with Ciprofloxacin. Cisapride The metabolism of Brentuximab vedotin can be decreased when combined with Cisapride. Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Brentuximab vedotin. Citalopram The metabolism of Brentuximab vedotin can be decreased when combined with Citalopram. Cladribine The risk or severity of adverse effects can be increased when Cladribine is combined with Brentuximab vedotin. Clarithromycin The serum concentration of Brentuximab vedotin can be increased when it is combined with Clarithromycin. Clevidipine The metabolism of Brentuximab vedotin can be increased when combined with Clevidipine. Clobazam The metabolism of Brentuximab vedotin can be increased when combined with Clobazam. Clobetasol propionate The metabolism of Brentuximab vedotin can be increased when combined with Clobetasol propionate. Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Brentuximab vedotin. Clofazimine The serum concentration of Brentuximab vedotin can be increased when it is combined with Clofazimine. Clofibrate The metabolism of Brentuximab vedotin can be increased when combined with Clofibrate. Clomifene The serum concentration of Brentuximab vedotin can be increased when it is combined with Clomifene. Clomipramine The metabolism of Clomipramine can be decreased when combined with Brentuximab vedotin. Clonidine The metabolism of Clonidine can be decreased when combined with Brentuximab vedotin. Clostridium The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Brentuximab vedotin. Clozapine The metabolism of Brentuximab vedotin can be increased when combined with Clozapine. Cobicistat The serum concentration of Brentuximab vedotin can be increased when it is combined with Cobicistat. Cobimetinib The metabolism of Cobimetinib can be decreased when combined with Brentuximab vedotin. Cocaine The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Cocaine. Colchicine The metabolism of Colchicine can be decreased when combined with Brentuximab vedotin. Conivaptan The serum concentration of Brentuximab vedotin can be increased when it is combined with Conivaptan. Conjugated estrogens Conjugated estrogens may increase the thrombogenic activities of Brentuximab vedotin. Copanlisib The metabolism of Copanlisib can be decreased when combined with Brentuximab vedotin. Corticotropin The metabolism of Brentuximab vedotin can be increased when combined with Corticotropin. Cortisone acetate The metabolism of Brentuximab vedotin can be increased when combined with Cortisone acetate. Corynebacterium The therapeutic efficacy of Corynebacterium diphtheriae toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Brentuximab vedotin. Crizotinib The metabolism of Brentuximab vedotin can be decreased when combined with Crizotinib. Curcumin The serum concentration of Brentuximab vedotin can be increased when it is combined with Curcumin. Cyclophosphamide The metabolism of Brentuximab vedotin can be increased when combined with Cyclophosphamide. Cyclosporine Brentuximab vedotin may increase the immunosuppressive activities of Cyclosporine. Cyproterone acetate The metabolism of Brentuximab vedotin can be decreased when combined with Cyproterone acetate. Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Brentuximab vedotin. Dabigatran etexilate The serum concentration of Brentuximab vedotin can be increased when it is combined with Dabigatran etexilate. Dabrafenib The serum concentration of Brentuximab vedotin can be decreased when it is combined with Dabrafenib. Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Brentuximab vedotin. Daclatasvir The serum concentration of Brentuximab vedotin can be increased when it is combined with Daclatasvir. Dacomitinib The serum concentration of Brentuximab vedotin can be increased when it is combined with Dacomitinib. Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Brentuximab vedotin. Dalfopristin The metabolism of Brentuximab vedotin can be decreased when combined with Dalfopristin. Danazol The metabolism of Brentuximab vedotin can be decreased when combined with Danazol. Daptomycin The serum concentration of Brentuximab vedotin can be increased when it is combined with Daptomycin. Daratumumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Daratumumab. Darbepoetin alfa The risk or severity of Thrombosis can be increased when Darbepoetin alfa is combined with Brentuximab vedotin. Darolutamide The serum concentration of Brentuximab vedotin can be increased when it is combined with Darolutamide. Darunavir The serum concentration of Brentuximab vedotin can be increased when it is combined with Darunavir. Dasabuvir The serum concentration of Brentuximab vedotin can be increased when it is combined with Dasabuvir. Dasatinib The metabolism of Brentuximab vedotin can be decreased when combined with Dasatinib. Daunorubicin The metabolism of Brentuximab vedotin can be decreased when combined with Daunorubicin. Decitabine The risk or severity of adverse effects can be increased when Decitabine is combined with Brentuximab vedotin. Deflazacort The metabolism of Brentuximab vedotin can be increased when combined with Deflazacort. Delavirdine The metabolism of Brentuximab vedotin can be decreased when combined with Delavirdine. Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Brentuximab vedotin. Desipramine The metabolism of Brentuximab vedotin can be decreased when combined with Desipramine. Desoximetasone The risk or severity of adverse effects can be increased when Desoximetasone is combined with Brentuximab vedotin. Desvenlafaxine The metabolism of Brentuximab vedotin can be decreased when combined with Desvenlafaxine. Deucravacitinib The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Deucravacitinib. Dexamethasone The metabolism of Brentuximab vedotin can be increased when combined with Dexamethasone. Dexamethasone acetate The serum concentration of Brentuximab vedotin can be decreased when it is combined with Dexamethasone acetate. Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Brentuximab vedotin. Dextropropoxyphene The metabolism of Brentuximab vedotin can be decreased when combined with Dextropropoxyphene. Dicloxacillin The metabolism of Brentuximab vedotin can be increased when combined with Dicloxacillin. Dienestrol Dienestrol may increase the thrombogenic activities of Brentuximab vedotin. Diethylstilbestrol The metabolism of Brentuximab vedotin can be decreased when combined with Diethylstilbestrol. Difluocortolone The metabolism of Brentuximab vedotin can be increased when combined with Difluocortolone. Digitoxin The metabolism of Digitoxin can be decreased when combined with Brentuximab vedotin. Digoxin The serum concentration of Brentuximab vedotin can be increased when it is combined with Digoxin. Digoxin Immune The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Brentuximab vedotin. Dihydroergocornine The metabolism of Brentuximab vedotin can be decreased when combined with Dihydroergocornine. Dihydroergocristine The metabolism of Brentuximab vedotin can be decreased when combined with Dihydroergocristine. Dihydroergotamine The metabolism of Brentuximab vedotin can be decreased when combined with Dihydroergotamine. Diltiazem The metabolism of Brentuximab vedotin can be decreased when combined with Diltiazem. Dimethyl fumarate The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dimethyl fumarate. Dimethyl sulfoxide The metabolism of Brentuximab vedotin can be decreased when combined with Dimethyl sulfoxide. Dinutuximab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dinutuximab. Diosmin The serum concentration of Brentuximab vedotin can be increased when it is combined with Diosmin. Diphenhydramine The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Diphenhydramine. Diroximel fumarate The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Diroximel fumarate. Docetaxel The metabolism of Brentuximab vedotin can be decreased when combined with Docetaxel. Dofetilide The metabolism of Dofetilide can be decreased when combined with Brentuximab vedotin. Dolutegravir The serum concentration of Brentuximab vedotin can be increased when it is combined with Dolutegravir. Dostarlimab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dostarlimab. Doxazosin The metabolism of Brentuximab vedotin can be decreased when combined with Doxazosin. Doxorubicin The metabolism of Brentuximab vedotin can be decreased when combined with Doxorubicin. Dronabinol The serum concentration of Dronabinol can be increased when it is combined with Brentuximab vedotin. Dronedarone The serum concentration of Brentuximab vedotin can be increased when it is combined with Dronedarone. Drospirenone The metabolism of Brentuximab vedotin can be decreased when combined with Drospirenone. Dulaglutide The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dulaglutide. Dupilumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Dupilumab. Durvalumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Durvalumab. Duvelisib The metabolism of Brentuximab vedotin can be decreased when combined with Duvelisib. Dyclonine The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Dyclonine. Ebastine The metabolism of Brentuximab vedotin can be decreased when combined with Ebastine. Ebola Zaire The therapeutic efficacy of Ebola Zaire vaccine (live, attenuated) can be decreased when used in combination with Brentuximab vedotin. Echinacea The metabolism of Brentuximab vedotin can be increased when combined with Echinacea. Eculizumab The risk or severity of adverse effects can be increased when Eculizumab is combined with Brentuximab vedotin. Edoxaban The serum concentration of Brentuximab vedotin can be increased when it is combined with Edoxaban. Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Brentuximab vedotin. Efavirenz The metabolism of Brentuximab vedotin can be decreased when combined with Efavirenz. Eflapegrastim The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Eflapegrastim. Eftrenonacog alfa The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Eftrenonacog alfa. Elagolix The serum concentration of Brentuximab vedotin can be increased when it is combined with Elagolix. Elbasvir The serum concentration of Brentuximab vedotin can be increased when it is combined with Elbasvir. Elexacaftor The metabolism of Brentuximab vedotin can be decreased when combined with Elexacaftor. Eliglustat The metabolism of Eliglustat can be decreased when combined with Brentuximab vedotin. Elotuzumab The risk or severity of adverse effects can be increased when Elotuzumab is combined with Brentuximab vedotin. Elvitegravir The metabolism of Brentuximab vedotin can be decreased when combined with Elvitegravir. Emapalumab The metabolism of Brentuximab vedotin can be increased when combined with Emapalumab. Emicizumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Emicizumab. Enasidenib The serum concentration of Brentuximab vedotin can be increased when it is combined with Enasidenib. Enfortumab vedotin The serum concentration of Brentuximab vedotin can be increased when it is combined with Enfortumab vedotin. Entrectinib The serum concentration of Brentuximab vedotin can be increased when it is combined with Entrectinib. Enzalutamide The serum concentration of Brentuximab vedotin can be decreased when it is combined with Enzalutamide. Epinephrine The metabolism of Brentuximab vedotin can be decreased when combined with Epinephrine. Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Brentuximab vedotin. Eptinezumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Eptinezumab. Erdafitinib The serum concentration of Brentuximab vedotin can be increased when it is combined with Erdafitinib. Erenumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Erenumab. Ergotamine The metabolism of Brentuximab vedotin can be decreased when combined with Ergotamine. Eribulin The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Eribulin. Erlotinib The metabolism of Brentuximab vedotin can be decreased when combined with Erlotinib. Ertugliflozin The serum concentration of Brentuximab vedotin can be increased when it is combined with Ertugliflozin. Erythromycin The serum concentration of Brentuximab vedotin can be increased when it is combined with Erythromycin. Erythropoietin The risk or severity of Thrombosis can be increased when Erythropoietin is combined with Brentuximab vedotin. Esketamine The metabolism of Brentuximab vedotin can be increased when combined with Esketamine. Eslicarbazepine The metabolism of Brentuximab vedotin can be increased when combined with Eslicarbazepine. Eslicarbazepine acetate The metabolism of Brentuximab vedotin can be increased when combined with Eslicarbazepine acetate. Esterified estrogens Esterified estrogens may increase the thrombogenic activities of Brentuximab vedotin. Estetrol The metabolism of Brentuximab vedotin can be decreased when combined with Estetrol. Estradiol Estradiol may increase the thrombogenic activities of Brentuximab vedotin. Estradiol acetate The metabolism of Brentuximab vedotin can be increased when combined with Estradiol acetate. Estradiol benzoate The metabolism of Brentuximab vedotin can be increased when combined with Estradiol benzoate. Estradiol cypionate The metabolism of Brentuximab vedotin can be increased when combined with Estradiol cypionate. Estradiol dienanthate The metabolism of Brentuximab vedotin can be increased when combined with Estradiol dienanthate. Estradiol valerate The metabolism of Brentuximab vedotin can be increased when combined with Estradiol valerate. Estramustine The risk or severity of adverse effects can be increased when Estramustine is combined with Brentuximab vedotin. Estriol Estriol may increase the thrombogenic activities of Brentuximab vedotin. Estrone Estrone may increase the thrombogenic activities of Brentuximab vedotin. Estrone sulfate Estrone sulfate may increase the thrombogenic activities of Brentuximab vedotin. Eszopiclone The metabolism of Eszopiclone can be decreased when combined with Brentuximab vedotin. Etanercept The metabolism of Brentuximab vedotin can be increased when combined with Etanercept. Ethambutol The metabolism of Brentuximab vedotin can be decreased when combined with Ethambutol. Ethanol The metabolism of Brentuximab vedotin can be increased when combined with Ethanol. Ethinylestradiol Ethinylestradiol may increase the thrombogenic activities of Brentuximab vedotin. Ethyl chloride The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Ethyl chloride. Etidocaine The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Etidocaine. Etoposide The metabolism of Etoposide can be decreased when combined with Brentuximab vedotin. Etoricoxib The metabolism of Brentuximab vedotin can be decreased when combined with Etoricoxib. Etravirine The metabolism of Brentuximab vedotin can be increased when combined with Etravirine. You Might Also Read Lapatinib; Uses, Dosage, Side Effects, Interactions Everolimus The serum concentration of Brentuximab vedotin can be increased when it is combined with Everolimus. Evolocumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Evolocumab. Fanolesomab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Fanolesomab. Favipiravir The serum concentration of Brentuximab vedotin can be increased when it is combined with Favipiravir. Fedratinib The serum concentration of Brentuximab vedotin can be increased when it is combined with Fedratinib. Felbamate The metabolism of Brentuximab vedotin can be increased when combined with Felbamate. Fenofibrate The metabolism of Brentuximab vedotin can be decreased when combined with Fenofibrate. Fentanyl The metabolism of Fentanyl can be decreased when combined with Brentuximab vedotin. Fexinidazole The metabolism of Brentuximab vedotin can be decreased when combined with Fexinidazole. Fexofenadine The serum concentration of Brentuximab vedotin can be increased when it is combined with Fexofenadine. Filgotinib The serum concentration of Brentuximab vedotin can be increased when it is combined with Filgotinib. Finerenone The serum concentration of Finerenone can be increased when it is combined with Brentuximab vedotin. Fingolimod Brentuximab vedotin may increase the immunosuppressive activities of Fingolimod. Flibanserin The serum concentration of Brentuximab vedotin can be increased when it is combined with Flibanserin. Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Brentuximab vedotin. Flucloxacillin The metabolism of Brentuximab vedotin can be increased when combined with Flucloxacillin. Fluconazole The serum concentration of Brentuximab vedotin can be increased when it is combined with Fluconazole. Flucytosine The risk or severity of adverse effects can be increased when Flucytosine is combined with Brentuximab vedotin. Fludarabine The risk or severity of adverse effects can be increased when Fludarabine is combined with Brentuximab vedotin. Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Brentuximab vedotin. Flunisolide The metabolism of Brentuximab vedotin can be increased when combined with Flunisolide. Fluocinolone The metabolism of Brentuximab vedotin can be increased when combined with Fluocinolone acetonide. Fluocinonide The metabolism of Brentuximab vedotin can be increased when combined with Fluocinonide. Fluocortolone The metabolism of Brentuximab vedotin can be increased when combined with Fluocortolone. Fluorometholone The risk or severity of adverse effects can be increased when Fluorometholone is combined with Brentuximab vedotin. Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Brentuximab vedotin. Fluoxetine The metabolism of Brentuximab vedotin can be decreased when combined with Fluoxetine. Fluprednisolone The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Fluprednisolone. Fluticasone The metabolism of Brentuximab vedotin can be increased when combined with Fluticasone. Fluticasone furoate The metabolism of Brentuximab vedotin can be increased when combined with Fluticasone furoate. Fluticasone propionate The metabolism of Brentuximab vedotin can be decreased when combined with Fluticasone propionate. Fluvoxamine The metabolism of Brentuximab vedotin can be decreased when combined with Fluvoxamine. Formestane The metabolism of Brentuximab vedotin can be increased when combined with Formestane. Fosamprenavir The metabolism of Brentuximab vedotin can be decreased when combined with Fosamprenavir. Fosaprepitant The metabolism of Brentuximab vedotin can be increased when combined with Fosaprepitant. Fosnetupitant The metabolism of Brentuximab vedotin can be decreased when combined with Fosnetupitant. Fosphenytoin The metabolism of Brentuximab vedotin can be increased when combined with Fosphenytoin. Fostamatinib The metabolism of Brentuximab vedotin can be decreased when combined with Fostamatinib. Fostemsavir The serum concentration of Brentuximab vedotin can be increased when it is combined with Fostemsavir. Fremanezumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Fremanezumab. Fusidic acid The metabolism of Brentuximab vedotin can be decreased when combined with Fusidic acid. Futibatinib The serum concentration of Brentuximab vedotin can be increased when it is combined with Futibatinib. Galcanezumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Galcanezumab. Gallium nitrate The risk or severity of adverse effects can be increased when Gallium nitrate is combined with Brentuximab vedotin. Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Brentuximab vedotin. Gemtuzumab The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Brentuximab vedotin. Gilteritinib The metabolism of Brentuximab vedotin can be decreased when combined with Gilteritinib. Ginkgo biloba The metabolism of Brentuximab vedotin can be decreased when combined with Ginkgo biloba. Glasdegib The serum concentration of Brentuximab vedotin can be increased when it is combined with Glasdegib. Glatiramer The risk or severity of adverse effects can be increased when Glatiramer is combined with Brentuximab vedotin. Glecaprevir The serum concentration of Brentuximab vedotin can be increased when it is combined with Glecaprevir. Glyburide The metabolism of Brentuximab vedotin can be decreased when combined with Glyburide. Glycerol The metabolism of Brentuximab vedotin can be increased when combined with Glycerol phenylbutyrate. Golimumab The metabolism of Brentuximab vedotin can be increased when combined with Golimumab. Grazoprevir The serum concentration of Brentuximab vedotin can be increased when it is combined with Grazoprevir. Griseofulvin The metabolism of Brentuximab vedotin can be increased when combined with Griseofulvin. Guselkumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Guselkumab. Ipilimumab The risk or severity of adverse effects can be increased when Ipilimumab is combined with Brentuximab vedotin. Irbesartan The metabolism of Brentuximab vedotin can be decreased when combined with Irbesartan. Irinotecan The metabolism of Irinotecan can be decreased when combined with Brentuximab vedotin. Isatuximab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Isatuximab. Isavuconazole The serum concentration of Brentuximab vedotin can be increased when it is combined with Isavuconazole. Isavuconazonium The serum concentration of Brentuximab vedotin can be increased when it is combined with Isavuconazonium. Isoniazid The metabolism of Brentuximab vedotin can be decreased when combined with Isoniazid. Isradipine The metabolism of Brentuximab vedotin can be decreased when combined with Isradipine. Istradefylline The serum concentration of Brentuximab vedotin can be increased when it is combined with Istradefylline. Itraconazole The serum concentration of Brentuximab vedotin can be increased when it is combined with Itraconazole. Ivacaftor The serum concentration of Brentuximab vedotin can be increased when it is combined with Ivacaftor. Ivosidenib The metabolism of Brentuximab vedotin can be increased when combined with Ivosidenib. Ixabepilone The serum concentration of Brentuximab vedotin can be increased when it is combined with Ixabepilone. Ixazomib The metabolism of Ixazomib can be decreased when combined with Brentuximab vedotin. Ixekizumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ixekizumab. COVID-19 Vaccine The therapeutic efficacy of Janssen COVID-19 Vaccine can be decreased when used in combination with Brentuximab vedotin. Japanese encephalitis The therapeutic efficacy of Japanese encephalitis virus strain sa 14-14-2 antigen (formaldehyde inactivated) can be decreased when used in combination with Brentuximab vedotin. Ketazolam The metabolism of Brentuximab vedotin can be decreased when combined with Ketazolam. Ketoconazole The serum concentration of Brentuximab vedotin can be increased when it is combined with Ketoconazole. Lacosamide The metabolism of Brentuximab vedotin can be decreased when combined with Lacosamide. Lanadelumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Lanadelumab. Lanreotide The metabolism of Brentuximab vedotin can be decreased when combined with Lanreotide. Lapatinib The serum concentration of Brentuximab vedotin can be increased when it is combined with Lapatinib. Larotrectinib The serum concentration of Brentuximab vedotin can be increased when it is combined with Larotrectinib. Lasmiditan The serum concentration of Brentuximab vedotin can be increased when it is combined with Lasmiditan. Ledipasvir The serum concentration of Brentuximab vedotin can be increased when it is combined with Ledipasvir. Lefamulin The serum concentration of Brentuximab vedotin can be increased when it is combined with Lefamulin. Leflunomide The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Leflunomide. Lemborexant The serum concentration of Brentuximab vedotin can be increased when it is combined with Lemborexant. Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Brentuximab vedotin. Lenvatinib The serum concentration of Brentuximab vedotin can be increased when it is combined with Lenvatinib. Lesinurad The metabolism of Brentuximab vedotin can be increased when combined with Lesinurad. Letermovir The metabolism of Brentuximab vedotin can be decreased when combined with Letermovir. Levacetylmethadol The metabolism of Levacetylmethadol can be decreased when combined with Brentuximab vedotin. Levamlodipine The serum concentration of Levamlodipine can be increased when it is combined with Brentuximab vedotin. Levobupivacaine The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Levobupivacaine. Levoketoconazole The serum concentration of Brentuximab vedotin can be increased when it is combined with Levoketoconazole. Levothyroxine The serum concentration of Brentuximab vedotin can be decreased when it is combined with Levothyroxine. Lidocaine The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Lidocaine. Linagliptin The serum concentration of Brentuximab vedotin can be increased when it is combined with Linagliptin. Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Brentuximab vedotin. Lomitapide The serum concentration of Brentuximab vedotin can be increased when it is combined with Lomitapide. Lomustine The risk or severity of adverse effects can be increased when Lomustine is combined with Brentuximab vedotin. Lonafarnib The serum concentration of Brentuximab vedotin can be increased when it is combined with Lonafarnib. Loncastuximab The serum concentration of Brentuximab vedotin can be increased when it is combined with Loncastuximab tesirine. Loperamide The serum concentration of Brentuximab vedotin can be increased when it is combined with Loperamide. Lopinavir The serum concentration of Brentuximab vedotin can be increased when it is combined with Lopinavir. Lorlatinib The serum concentration of Brentuximab vedotin can be decreased when it is combined with Lorlatinib. Losartan The metabolism of Brentuximab vedotin can be decreased when combined with Losartan. Lovastatin The metabolism of Lovastatin can be decreased when combined with Brentuximab vedotin. Loxapine The serum concentration of Brentuximab vedotin can be increased when it is combined with Loxapine. Lumacaftor The serum concentration of Brentuximab vedotin can be increased when it is combined with Lumacaftor. Lusutrombopag The serum concentration of Brentuximab vedotin can be increased when it is combined with Lusutrombopag. Maftivimab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Maftivimab. Magnesium The serum concentration of Magnesium can be decreased when it is combined with Brentuximab vedotin. Manidipine The metabolism of Brentuximab vedotin can be decreased when combined with Manidipine. Mannitol The serum concentration of Brentuximab vedotin can be increased when it is combined with Mannitol. Margetuximab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Margetuximab. Maribavir The serum concentration of Brentuximab vedotin can be increased when it is combined with Maribavir. Mavacamten The serum concentration of Brentuximab vedotin can be decreased when it is combined with Mavacamten. Measles virus vaccine The therapeutic efficacy of Measles virus vaccine live attenuated can be decreased when used in combination with Brentuximab vedotin. Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Brentuximab vedotin. Medroxyprogesterone The metabolism of Brentuximab vedotin can be increased when combined with Medroxyprogesterone acetate. Mefloquine The serum concentration of Brentuximab vedotin can be increased when it is combined with Mefloquine. Meloxicam The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Meloxicam. Melphalan The risk or severity of adverse effects can be increased when Melphalan is combined with Brentuximab vedotin. Meningococcal The therapeutic efficacy of Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM197 conjugate vaccine can be decreased when used in combination with Brentuximab vedotin. Meperidine The metabolism of Brentuximab vedotin can be decreased when combined with Meperidine. Mepivacaine The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Mepivacaine. Mepolizumab The risk or severity of adverse effects can be increased when Mepolizumab is combined with Brentuximab vedotin. Meprednisone The metabolism of Brentuximab vedotin can be increased when combined with Meprednisone. Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Brentuximab vedotin. Mestranol Mestranol may increase the thrombogenic activities of Brentuximab vedotin. Methadone The metabolism of Brentuximab vedotin can be decreased when combined with Methadone. Methimazole The metabolism of Brentuximab vedotin can be decreased when combined with Methimazole. Methotrexate The metabolism of Methotrexate can be decreased when combined with Brentuximab vedotin. Methoxy polyethylene The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Brentuximab vedotin. Methylene blue The serum concentration of Brentuximab vedotin can be increased when it is combined with Methylene blue. Methylergometrine The metabolism of Brentuximab vedotin can be decreased when combined with Methylergometrine. Methylphenobarbital The metabolism of Brentuximab vedotin can be increased when combined with Methylphenobarbital. Methylprednisolone The metabolism of Brentuximab vedotin can be increased when combined with Methylprednisolone. Methylprednisone The metabolism of Brentuximab vedotin can be decreased when combined with Methylprednisone. Methysergide The metabolism of Brentuximab vedotin can be decreased when combined with Methysergide. Metreleptin The metabolism of Brentuximab vedotin can be increased when combined with Metreleptin. Metronidazole The metabolism of Brentuximab vedotin can be decreased when combined with Metronidazole. Metyrapone The metabolism of Brentuximab vedotin can be increased when combined with Metyrapone. Miconazole The metabolism of Brentuximab vedotin can be decreased when combined with Miconazole. Pimozide The metabolism of Pimozide can be decreased when combined with Brentuximab vedotin. Piperaquine The metabolism of Brentuximab vedotin can be decreased when combined with Piperaquine. Pirfenidone The risk or severity of adverse effects can be increased when Pirfenidone is combined with Brentuximab vedotin. Pitolisant The serum concentration of Brentuximab vedotin can be decreased when it is combined with Pitolisant. Polatuzumab vedotin The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Polatuzumab vedotin. Polyestradiol phosphate Polyestradiol phosphate may increase the thrombogenic activities of Brentuximab vedotin. Pomalidomide The metabolism of Pomalidomide can be decreased when combined with Brentuximab vedotin. Ponatinib The serum concentration of Brentuximab vedotin can be increased when it is combined with Ponatinib. Ponesimod The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ponesimod. Posaconazole The metabolism of Brentuximab vedotin can be decreased when combined with Posaconazole. Pralatrexate The risk or severity of adverse effects can be increased when Pralatrexate is combined with Brentuximab vedotin. Pralsetinib The serum concentration of Brentuximab vedotin can be increased when it is combined with Pralsetinib. Pramocaine The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Pramocaine. Pravastatin The serum concentration of Brentuximab vedotin can be increased when it is combined with Pravastatin. Prednisolone The metabolism of Brentuximab vedotin can be increased when combined with Prednisolone. Prednisolone acetate The metabolism of Brentuximab vedotin can be increased when combined with Prednisolone acetate. Prednisolone phosphate The serum concentration of Brentuximab vedotin can be decreased when it is combined with Prednisolone phosphate. Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Brentuximab vedotin. Prednisone acetate The metabolism of Brentuximab vedotin can be increased when combined with Prednisone acetate. Pretomanid The metabolism of Brentuximab vedotin can be decreased when combined with Pretomanid. Prilocaine The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Prilocaine. Primaquine The metabolism of Brentuximab vedotin can be decreased when combined with Primaquine. Primidone The metabolism of Brentuximab vedotin can be increased when combined with Primidone. Probenecid The metabolism of Brentuximab vedotin can be increased when combined with Probenecid. Procaine The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Procaine. Procarbazine The risk or severity of adverse effects can be increased when Procarbazine is combined with Brentuximab vedotin. Propafenone The serum concentration of Brentuximab vedotin can be increased when it is combined with Propafenone. Proparacaine The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Proparacaine. Propofol The metabolism of Brentuximab vedotin can be decreased when combined with Propofol. Propoxycaine The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Propoxycaine. Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Brentuximab vedotin. Prucalopride The metabolism of Prucalopride can be decreased when combined with Brentuximab vedotin. Quinestrol Quinestrol may increase the thrombogenic activities of Brentuximab vedotin. Quinidine The serum concentration of Brentuximab vedotin can be increased when it is combined with Quinidine. Quinine The serum concentration of Brentuximab vedotin can be increased when it is combined with Quinine. Quinupristin The metabolism of Brentuximab vedotin can be decreased when combined with Quinupristin. immune globulin, The therapeutic efficacy of Rabies immune globulin, human can be decreased when used in combination with Brentuximab vedotin. Rabies virus inactivated The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Brentuximab vedotin. Rabies virus inactivated The therapeutic efficacy of Rabies virus inactivated antigen, B can be decreased when used in combination with Brentuximab vedotin. Raloxifene The metabolism of Brentuximab vedotin can be decreased when combined with Raloxifene. Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Brentuximab vedotin. Ramucirumab The risk or severity of adverse effects can be increased when Ramucirumab is combined with Brentuximab vedotin. Ranibizumab The risk or severity of adverse effects can be increased when Ranibizumab is combined with Brentuximab vedotin. Ranolazine The serum concentration of Brentuximab vedotin can be increased when it is combined with Ranolazine. Ravulizumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ravulizumab. Raxibacumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Raxibacumab. Regorafenib The serum concentration of Brentuximab vedotin can be increased when it is combined with Regorafenib. Relugolix The serum concentration of Brentuximab vedotin can be increased when it is combined with Relugolix. Remdesivir The metabolism of Brentuximab vedotin can be decreased when combined with Remdesivir. Reserpine The serum concentration of Brentuximab vedotin can be increased when it is combined with Reserpine. Reslizumab The risk or severity of adverse effects can be increased when Reslizumab is combined with Brentuximab vedotin. Retapamulin The metabolism of Retapamulin can be decreased when combined with Brentuximab vedotin. Revefenacin The serum concentration of Brentuximab vedotin can be increased when it is combined with Revefenacin. Ribociclib The metabolism of Brentuximab vedotin can be decreased when combined with Ribociclib. Rifabutin The metabolism of Brentuximab vedotin can be increased when combined with Rifabutin. Rifampicin The serum concentration of Brentuximab vedotin can be decreased when it is combined with Rifampicin. Rifamycin The serum concentration of Brentuximab vedotin can be increased when it is combined with Rifamycin. Rifapentine The metabolism of Brentuximab vedotin can be increased when combined with Rifapentine. Rilonacept The metabolism of Brentuximab vedotin can be increased when combined with Rilonacept. Rilpivirine The metabolism of Brentuximab vedotin can be decreased when combined with Rilpivirine. Rimegepant The serum concentration of Brentuximab vedotin can be increased when it is combined with Rimegepant. Riociguat The serum concentration of Brentuximab vedotin can be increased when it is combined with Riociguat. Ripretinib The serum concentration of Brentuximab vedotin can be increased when it is combined with Ripretinib. Risankizumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Risankizumab. Ritonavir The serum concentration of Brentuximab vedotin can be increased when it is combined with Ritonavir. Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Brentuximab vedotin. Rivaroxaban The serum concentration of Brentuximab vedotin can be increased when it is combined with Rivaroxaban. Rofecoxib The metabolism of Brentuximab vedotin can be increased when combined with Rofecoxib. Roflumilast The serum concentration of Roflumilast can be increased when it is combined with Brentuximab vedotin. Rolapitant The serum concentration of Brentuximab vedotin can be increased when it is combined with Rolapitant. Romidepsin The metabolism of Romidepsin can be decreased when combined with Brentuximab vedotin. Romosozumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Romosozumab. Ropeginterferon The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Ropeginterferon alfa-2b. Ropivacaine The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Ropivacaine. Rosuvastatin The metabolism of Brentuximab vedotin can be decreased when combined with Rosuvastatin. Rotavirus vaccine The therapeutic efficacy of Rotavirus vaccine can be decreased when used in combination with Brentuximab vedotin. Roxithromycin The metabolism of Brentuximab vedotin can be decreased when combined with Roxithromycin. Rubella virus vaccine The risk or severity of infection can be increased when Rubella virus vaccine is combined with Brentuximab vedotin. Rucaparib The metabolism of Brentuximab vedotin can be decreased when combined with Rucaparib. Rufinamide The metabolism of Brentuximab vedotin can be increased when combined with Rufinamide. Ruxolitinib The metabolism of Ruxolitinib can be decreased when combined with Brentuximab vedotin. Sacituzumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Sacituzumab govitecan. Sapropterin The serum concentration of Brentuximab vedotin can be increased when it is combined with Sapropterin. Saquinavir The serum concentration of Brentuximab vedotin can be increased when it is combined with Saquinavir. Sarecycline The serum concentration of Brentuximab vedotin can be increased when it is combined with Sarecycline. Sarilumab The metabolism of Brentuximab vedotin can be increased when combined with Sarilumab. Satralizumab The serum concentration of Brentuximab vedotin can be decreased when it is combined with Satralizumab. Secobarbital The metabolism of Brentuximab vedotin can be increased when combined with Secobarbital. Secukinumab The metabolism of Brentuximab vedotin can be increased when combined with Secukinumab. Selexipag The serum concentration of Brentuximab vedotin can be increased when it is combined with Selexipag. Selumetinib The serum concentration of Brentuximab vedotin can be increased when it is combined with Selumetinib. Sildenafil The serum concentration of Brentuximab vedotin can be increased when it is combined with Sildenafil. Silodosin The serum concentration of Brentuximab vedotin can be increased when it is combined with Silodosin. Siltuximab The metabolism of Brentuximab vedotin can be increased when combined with Siltuximab. Simeprevir The serum concentration of Brentuximab vedotin can be increased when it is combined with Simeprevir. Simvastatin The serum concentration of Brentuximab vedotin can be increased when it is combined with Simvastatin. Siponimod The metabolism of Siponimod can be decreased when combined with Brentuximab vedotin. Sipuleucel-T The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Brentuximab vedotin. Sirolimus The metabolism of Sirolimus can be decreased when combined with Brentuximab vedotin. Sitagliptin The serum concentration of Brentuximab vedotin can be increased when it is combined with Sitagliptin. You Might Also Read Dactinomycin - Uses, Dosage, Side Effects, Interaction Somatostatin The metabolism of Brentuximab vedotin can be decreased when combined with Somatostatin. Somatrogon The metabolism of Brentuximab vedotin can be increased when combined with Somatrogon. Sonidegib The metabolism of Sonidegib can be decreased when combined with Brentuximab vedotin. Sorafenib The serum concentration of Brentuximab vedotin can be increased when it is combined with Sorafenib. Sotagliflozin The serum concentration of Brentuximab vedotin can be increased when it is combined with Sotagliflozin. Sotorasib The serum concentration of Brentuximab vedotin can be decreased when it is combined with Sotorasib. Sotrovimab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Sotrovimab. Spesolimab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Spesolimab. St. John’s Wort The serum concentration of Brentuximab vedotin can be decreased when it is combined with St. John’s Wort. Stiripentol The metabolism of Brentuximab vedotin can be decreased when combined with Stiripentol. Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Brentuximab vedotin. Sulesomab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Sulesomab. Sulfamethoxazole The risk or severity of myelosuppression can be increased when Sulfamethoxazole is combined with Brentuximab vedotin. Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Brentuximab vedotin. Sulfinpyrazone The metabolism of Brentuximab vedotin can be increased when combined with Sulfinpyrazone. Sunitinib The metabolism of Sunitinib can be decreased when combined with Brentuximab vedotin. Sutimlimab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Sutimlimab. Suvorexant The serum concentration of Brentuximab vedotin can be increased when it is combined with Suvorexant. Synthetic Conjugated Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Brentuximab vedotin. Synthetic Conjugated Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Brentuximab vedotin. Tacrolimus The serum concentration of Tacrolimus can be increased when it is combined with Brentuximab vedotin. Tafasitamab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tafasitamab. Talazoparib The serum concentration of Brentuximab vedotin can be increased when it is combined with Talazoparib. Tamoxifen The serum concentration of Brentuximab vedotin can be increased when it is combined with Tamoxifen. Tasimelteon The metabolism of Brentuximab vedotin can be decreased when combined with Tasimelteon. Tazemetostat The metabolism of Brentuximab vedotin can be decreased when combined with Tazemetostat. Technetium The serum concentration of Brentuximab vedotin can be increased when it is combined with Technetium Tc-99m sestamibi. Tecovirimat The metabolism of Brentuximab vedotin can be increased when combined with Tecovirimat. Tegaserod The serum concentration of Brentuximab vedotin can be increased when it is combined with Tegaserod. Telaprevir The serum concentration of Brentuximab vedotin can be increased when it is combined with Telaprevir. Telithromycin The metabolism of Brentuximab vedotin can be decreased when combined with Telithromycin. Telotristat ethyl The serum concentration of Brentuximab vedotin can be decreased when it is combined with Telotristat ethyl. Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Brentuximab vedotin. Temsirolimus The serum concentration of Brentuximab vedotin can be increased when it is combined with Temsirolimus. Teniposide The metabolism of Brentuximab vedotin can be decreased when combined with Teniposide. Tenofovir The metabolism of Brentuximab vedotin can be decreased when combined with Tenofovir alafenamide. Tenofovir disoproxil The serum concentration of Brentuximab vedotin can be increased when it is combined with Tenofovir disoproxil. Tepotinib The serum concentration of Brentuximab vedotin can be increased when it is combined with Tepotinib. Teprotumumab The risk or severity of adverse effects can be increased when Teprotumumab is combined with Brentuximab vedotin. Terbinafine The metabolism of Brentuximab vedotin can be increased when combined with Terbinafine. Terfenadine The metabolism of Brentuximab vedotin can be decreased when combined with Terfenadine. Teriflunomide The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Teriflunomide. Testosterone The metabolism of Brentuximab vedotin can be increased when combined with Testosterone. Tetanus immune The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tetanus immune globulin, human. Tetracaine The risk or severity of methemoglobinemia can be increased when Brentuximab vedotin is combined with Tetracaine. Tetracycline The metabolism of Brentuximab vedotin can be decreased when combined with Tetracycline. Tezacaftor The serum concentration of Brentuximab vedotin can be increased when it is combined with Tezacaftor. Tezepelumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tezepelumab. Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Brentuximab vedotin. Theophylline The metabolism of Theophylline can be decreased when combined with Brentuximab vedotin. Thiamylal The metabolism of Brentuximab vedotin can be increased when combined with Thiamylal. Thiotepa The metabolism of Thiotepa can be decreased when combined with Brentuximab vedotin. Tibolone Tibolone may increase the thrombogenic activities of Brentuximab vedotin. Ticagrelor The serum concentration of Brentuximab vedotin can be increased when it is combined with Ticagrelor. Tick-borne encephalitis The therapeutic efficacy of Tick-borne encephalitis vaccine (whole virus, inactivated) can be decreased when used in combination with Brentuximab vedotin. Tildrakizumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tildrakizumab. Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Brentuximab vedotin. Tipranavir The serum concentration of Brentuximab vedotin can be increased when it is combined with Tipranavir. Tisotumab vedotin The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tisotumab vedotin. Tivozanib The serum concentration of Brentuximab vedotin can be increased when it is combined with Tivozanib. Tixagevimab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tixagevimab. Tixocortol The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tixocortol. Tocilizumab The metabolism of Brentuximab vedotin can be increased when combined with Tocilizumab. Tofacitinib The metabolism of Tofacitinib can be decreased when combined with Brentuximab vedotin. Tolvaptan The metabolism of Tolvaptan can be decreased when combined with Brentuximab vedotin. Topiramate The metabolism of Brentuximab vedotin can be increased when combined with Topiramate. Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Brentuximab vedotin. Toremifene The serum concentration of Brentuximab vedotin can be increased when it is combined with Toremifene. Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Brentuximab vedotin. Trabectedin The metabolism of Trabectedin can be decreased when combined with Brentuximab vedotin. Tralokinumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tralokinumab. Tramadol The metabolism of Tramadol can be decreased when combined with Brentuximab vedotin. Trastuzumab Trastuzumab may increase the neutropenic activities of Brentuximab vedotin. Trastuzumab deruxtecan The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Trastuzumab deruxtecan. Trastuzumab emtansine The metabolism of Trastuzumab emtansine can be decreased when combined with Brentuximab vedotin. Trazodone The serum concentration of Brentuximab vedotin can be decreased when it is combined with Trazodone. Tremelimumab The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Tremelimumab. Tretinoin The risk or severity of adverse effects can be increased when Tretinoin is combined with Brentuximab vedotin. Triamcinolone The metabolism of Brentuximab vedotin can be increased when combined with Triamcinolone. Triclabendazole The metabolism of Brentuximab vedotin can be decreased when combined with Triclabendazole. Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Brentuximab vedotin. Trilaciclib The serum concentration of Brentuximab vedotin can be increased when it is combined with Trilaciclib. Trilostane The risk or severity of adverse effects can be increased when Trilostane is combined with Brentuximab vedotin. Troglitazone The metabolism of Brentuximab vedotin can be increased when combined with Troglitazone. Troleandomycin The metabolism of Brentuximab vedotin can be decreased when combined with Troleandomycin. Tucatinib The metabolism of Tucatinib can be decreased when combined with Brentuximab vedotin. Typhoid vaccine The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Brentuximab vedotin. Typhoid Vaccine Live The risk or severity of infection can be increased when Typhoid Vaccine Live is combined with Brentuximab vedotin. Typhoid Vi The therapeutic efficacy of Typhoid Vi polysaccharide vaccine can be decreased when used in combination with Brentuximab vedotin. Ubrogepant The serum concentration of Brentuximab vedotin can be increased when it is combined with Ubrogepant. Umbralisib The serum concentration of Brentuximab vedotin can be increased when it is combined with Umbralisib. Umeclidinium The serum concentration of Brentuximab vedotin can be increased when it is combined with Umeclidinium. Upadacitinib The risk or severity of adverse effects can be increased when Brentuximab vedotin is combined with Upadacitinib. Ustekinumab The risk or severity of adverse effects can be increased when Ustekinumab is combined with Brentuximab vedotin. Valproic acid The metabolism of Brentuximab vedotin can be decreased when combined with Valproic acid. Vandetanib The serum concentration of Brentuximab vedotin can be increased when it is combined with Vandetanib. Vardenafil The metabolism of Vardenafil can be decreased when combined with Brentuximab vedotin. Pregnancy and Lactation Pregnancy May cause fetal harm. Lactation Not known whether distributed into milk. Effects on nursing infants and on milk production also unknown. Discontinue nursing. How should this medicine be used? Brentuximab vedotin injection comes as a powder to be mixed with fluid and injected over 30 minutes intravenously (into a vein) by a doctor or nurse in a medical office or hospital. When brentuximab vedotin is given to treat Hodgkin’s lymphoma, sALCL, or PTCL, it is usually injected once every 3 weeks for as long as your doctor recommends that you receive treatment. When brentuximab vedotin is used in combination with chemotherapy to treat Hodgkin lymphoma as a first treatment, it is usually injected once every 2 weeks for as long as your doctor recommends that you receive treatment. Brentuximab vedotin injection may cause serious allergic reactions, which usually occur during the infusion of the medication or within 24 hours of receiving a dose. You may receive certain medications before your infusion to prevent an allergic reaction if you had a reaction with previous treatment. Your doctor will watch you carefully while you are receiving brentuximab vedotin. If you experience any of the following symptoms, tell your doctor immediately: fever, chills, rash, hives, itching, or difficulty breathing. Your doctor may need to delay your treatment, adjust your dose, or stop your treatment if you experience certain side effects. Be sure to tell your doctor how you are feeling during your treatment with brentuximab vedotin injection. Other uses for this medicine This medication may be prescribed for other uses; ask your doctor or pharmacist for more information. What special precautions should I follow? Before receiving brentuximab vedotin injection, tell your doctor and pharmacist if you are allergic to brentuximab vedotin, any other medications, or any of the ingredients in brentuximab vedotin injection. Ask your pharmacist for a list of the ingredients. tell your doctor if you are receiving bleomycin. Your doctor will probably tell you not to use brentuximab vedotin injection if you are receiving this medication. tell your doctor and pharmacist what other prescription and nonprescription medications, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Be sure to mention any of the following: clarithromycin (Biaxin, in PrevPac), indinavir (Crixivan), itraconazole (Sporanox), ketoconazole, nefazodone, nelfinavir (Viracept), rifampin (Rifadin, Rimactane, in Rifamate, in Rifater), and ritonavir (Norvir, in Kaletra). Your doctor may need to change the doses of your medications or monitor you carefully for side effects. tell your doctor if you have or have ever had liver or kidney disease. tell your doctor if you are pregnant or plan to become pregnant. If you are a woman who is able to become pregnant, you must take a pregnancy test before starting treatment and use effective birth control during your treatment and for 6 months after your final dose. If you are male with a female partner who is pregnant or could become pregnant, you must use effective birth control during your treatment and for 6 months after your final dose. Talk to your doctor about birth control methods that you can use. If you or your partner become pregnant while receiving brentuximab vedotin injection, call your doctor immediately. Brentuximab vedotin injection may harm the fetus. tell your doctor if you are breastfeeding. You should not breastfeed while you are receiving brentuximab vedotin injection. you should know that this medication may decrease fertility in men. Talk to your doctor about the risks of receiving brentuximab vedotin injection. References https://pubchem.ncbi.nlm.nih.gov/substance/178103378 https://go.drugbank.com/drugs/DB08870 https://en.wikipedia.org/wiki/Brentuximab_vedotin https://www.drugs.com/mtm/brentuximab-vedotin.html Show More